Last edition
News about "Phase 2b Elumina clinical trial "
AtaiBeckley Completes Patient Dosing in Phase 2b Trial of VLS-01 for Treatment-Resistant Depression
AtaiBeckley has completed dosing the final patient in its Phase 2b Elumina trial evaluating VLS-01 for treatment-resistant depression. The company expects topline results in the fourth quarter of 2026 and plans to expand the therapy into major depressive disorder and generalized anxiety disorder, subject to positive clinical outcomes.
Phase 2b Elumina Clinical Trial | 07/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy